GLP-1 side effects explained by a nurse: what holds up?

What's this video probably claiming?

Charge nurse Keasha is almost certainly walking her 45K viewers through the common side effects of GLP-1 receptor agonists, drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Based on the caption framing, she's likely covering nausea, vomiting, constipation, fatigue, and possibly some of the less-discussed effects like gastroparesis risk or muscle loss. Nurses in this content category tend to position themselves as the plain-English explainer the prescribing doctor didn't have time to be. That's genuinely useful. But the quality of that explanation depends heavily on whether it tracks with what the clinical trial data actually shows, versus what's circulating in patient communities and Facebook groups. The hashtag 'patientadvocate' suggests an accessible, reassuring tone, which can sometimes soften or oversimplify the real risk profile of these medications.

What does the science actually show?

The side effect data on GLP-1 agonists is actually quite solid at this point. The SUSTAIN and STEP trial programs for semaglutide showed that gastrointestinal events, primarily nausea, vomiting, diarrhea, and constipation, affect roughly 40-44% of patients on 2.4mg weekly semaglutide, versus about 16% on placebo (Wilding et al., 2021, NEJM). Most GI symptoms are dose-dependent and peak during the titration phase. The SURMOUNT-1 trial for tirzepatide showed similar GI rates at the 15mg dose, with nausea hitting around 33% of participants (Jastreboff et al., 2022, NEJM). Less commonly discussed but clinically relevant: a 2024 study in JAMA using a large insurance claims database found patients on GLP-1s had significantly elevated rates of gastroparesis, pancreatitis, and bowel obstruction compared to bupropion-naltrexone users (Sodhi et al., 2023, JAMA). That last finding is still being debated, but it shouldn't be glossed over in a patient-facing video.

Where does the social media noise diverge from clinical reality?

The gap between TikTok GLP-1 content and clinical reality usually shows up in a few predictable places. First, the framing of side effects as universally temporary and manageable. They often are, but for some patients nausea is severe enough to cause discontinuation, which happened to roughly 7% of semaglutide users in STEP 1 (Wilding et al., 2021). Second, the 'Ozempic face' and muscle loss conversation is frequently handled poorly. Lean mass loss is real and dose-dependent, with some analyses suggesting 25-39% of total weight lost on semaglutide is lean tissue (Blundell et al., 2017, Diabetes Obesity and Metabolism). Third, injection site reactions, thyroid C-cell concerns (a black box warning for liraglutide and semaglutide based on rodent data), and the emerging conversation around suicidal ideation signals being reviewed by the FDA are rarely touched in patient-facing social content. The reassuring nurse voice is valuable. But 'I'll give you an explanation' implies completeness that a short TikTok structurally cannot deliver.

What should you actually know?

If you're on a GLP-1 or considering one, the side effect picture is genuinely manageable for most people, but it's not as simple as 'you'll feel a little nauseous at first.' A few things worth knowing: dose titration schedules exist for a reason, and rushing them correlates directly with more severe GI events. Anti-nausea strategies like ginger, smaller meals, and timing injections strategically have some clinical support. Protein intake and resistance training matter significantly if you want to preserve lean mass, and that's not a minor aesthetic concern, it affects metabolic rate and long-term outcomes. Anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not be on semaglutide or liraglutide, full stop. And if you're experiencing severe abdominal pain, that warrants a call to your provider, not a TikTok comment section. A nurse educator on social media can be a genuinely good resource. She just can't replace a conversation with your actual prescriber about your specific history.